Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05691829 | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC(IRRADIATE-Lung) | terminated | Phase 2 | 19 | NYU Langone HealthOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 11 | Numab Therapeutics AGINDUSTRY | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03087708 | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | terminated | Phase 2 | 50 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT02613299 | Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma | terminated | — | 5 | Mayo ClinicOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | terminated | Phase 1 | 5 | Craig L Slingluff, JrOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05788926 | A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) | terminated | Phase 1 | 22 | TransgeneINDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT01726309 | Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 | terminated | — | 161 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | terminated | Phase 1 | 57 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05573035 | A Study to Investigate LYL845 in Adults With Solid Tumors | terminated | Phase 1 | 39 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | terminated | — | 10 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04921358 | Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | terminated | Phase 3 | 377 | BeiGeneINDUSTRY | 2 | Jun 29, 2025 | clinicaltrials |
| NCT06643117 | Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)(Lotus) | terminated | Phase 3 | 25 | Formycon AGINDUSTRY | 3 | Jun 26, 2025 | clinicaltrials |
| NCT04735471 | A Phase 1 Study of ADI-001 in B Cell Malignancies(GLEAN-1) | terminated | Phase 1 | 34 | Adicet TherapeuticsINDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03292133 | A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | terminated | Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05251805 | The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery | terminated | N/A | 4 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | terminated | Phase 1 / Phase 2 | 45 | Bridge Biotherapeutics, Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06140407 | Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer | terminated | Phase 2 | 1 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | terminated | Phase 1 | 221 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03505710 | DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer(DESTINY-Lung01) | terminated | Phase 2 | 181 | Daiichi SankyoINDUSTRY | 5 | May 30, 2025 | clinicaltrials |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | terminated | Phase 1 | 85 | PfizerINDUSTRY | 5 | May 28, 2025 | clinicaltrials |
| NCT04441138 | Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC(ESR1814205) | terminated | Phase 2 | 10 | Rush University Medical CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 265 | ImmunoGenesisINDUSTRY | 10 | May 16, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT02745548 | Bronchial Mapping (GCC 1635) | terminated | — | 23 | University of Maryland, BaltimoreOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02991651 | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC | terminated | Phase 1 | 12 | Io TherapeuticsINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT04567251 | Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy(SPiRiT) | terminated | — | 5 | Duke UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 3 | Vitrac Therapeutics, LLCINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | terminated | Phase 1 | 22 | Coherus Oncology, Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06003075 | Induction Chemo-Nivo in Unresectable Stage III NSCLC | terminated | Phase 2 | 1 | Ralph G ZinnerOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | terminated | Phase 1 | 6 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 7 | Faeth TherapeuticsINDUSTRY | 1 | Apr 24, 2025 | clinicaltrials |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer(KEYNOTE B36) | terminated | Phase 2 | 15 | NovoCure GmbHINDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 40 | NextCure, Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05790460 | Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer(TESTING) | terminated | N/A | 55 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT04925986 | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | terminated | Phase 2 | 9 | Sarah GoldbergOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06094296 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 16, 2025 | clinicaltrials |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | terminated | Phase 1 | 241 | Novartis PharmaceuticalsINDUSTRY | 11 | Apr 13, 2025 | clinicaltrials |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | terminated | Phase 1 | 63 | Mirati Therapeutics Inc.INDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 14 | Allist Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 3, 2025 | clinicaltrials |
| NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | terminated | N/A | 116 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | terminated | Phase 1 / Phase 2 | 222 | Kymab LimitedINDUSTRY | 6 | Apr 2, 2025 | clinicaltrials |
| NCT04512430 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | terminated | Phase 2 | 4 | Fundación GECPOTHER | 1 | Apr 2, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 29, 2025source: clinicaltrials